What this study is
The purpose of this registry is to (A) better describe the incidence and prevalence of Amyotrophic Lateral Sclerosis (ALS) in the United States;(B) examine appropriate factors, such as environmental and occupational, that may be associated with the disease; (C) better outline key demographic factors (such as age, race or ethnicity, gender, and family history of individuals who are diagnosed with the disease) associated with the disease; and (D) better examine the connection between ALS and other motor neuron disorders that can be confused with ALS, misdiagnosed as ALS, and in some cases progress to ALS.
Study details
- Sponsor
- Centers for Disease Control and Prevention
- Conditions
- Amyotrophic Lateral Sclerosis
- Enrolling
- 30,000 people
- Starts
- 2010-10
- Est. completion
- 2040-12
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- U.S. citizens 18 years of age or older
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openCDC
Atlanta, Georgia, United States
- Paul Mehta, MD · Contact770-488-0556PMehta1@cdc.gov
- Kevin Horton, DrPH, MSPH · Contact770-488-1555dhorton@cdc.gov
- Paul Mehta, MD · Principal investigator
Recruiting
Study team
Sponsor
Centers for Disease Control and Prevention
Study ID CDC-NCEH/ATSDR-5768
Principal investigator
Paul Mehta, MD
Centers for Disease Control and Prevention
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.